For decades, Parkinson's disease has been understood as a story of accumulation — a toxic protein spreading through the brain like a slow fire — yet the door through which that fire passed remained unknown. Researchers at Yale have now identified two proteins, mGluR4 and NPDC1, that serve as that doorway, ferrying misfolded α-synuclein from dying neurons into healthy ones. When those proteins were removed in mice, the disease stopped advancing entirely. In a condition that has long offered patients only the management of symptoms rather than the slowing of fate, this discovery marks a meaningf
Yale researchers identify proteins that spread Parkinson's toxin, offering new treatment target
Parkinson's disease affects 1.1 million Americans with nearly 90,000 new diagnoses annually, causing progressive motor dysfunction including tremors, balance impairment, and movement slowness.
If we understood how it gets into neurons, we could perhaps block the progression
Mark
So the researchers found two proteins that act like doors for this toxic protein. But how did they know to look at the cell surface in the first place?
Mimi
They reasoned that if α-synuclein is moving from one neuron to another, it has to attach to something on the outside of the cell first. It can't just pass through the membrane on its own. So they tested thousands of surface proteins to see which ones would bind to it.
Mark
And out of 4,400 groups of cells, only 16 proteins bound to it?
Mimi
Yes. That's how specific the interaction is. Most proteins had no interaction at all. But those 16 that did bind—they found two that were particularly important and located exactly where the disease does the most damage.
Mark
The mice without these proteins didn't get sick at all?
Mimi
Not when exposed to the toxic protein, no. And in mice that already had Parkinson's, removing the genes for these proteins slowed the disease progression and reduced death risk. It's a strong signal that blocking these proteins could work as a therapy.
Mark
But we're still talking about mice, not people.
Mimi
That's true. The leap from mouse models to human treatment is significant. But this gives researchers a specific molecular target to work toward, which is something they didn't have before. It changes the question from "how does this happen" to "how do we block it."
Mark
And the urgency is real—1.1 million Americans already have Parkinson's.
Mimi
Exactly. And that number will only grow as the population ages. Current treatments don't slow the disease, they just manage symptoms. A therapy that actually slowed progression would be transformative.
Le Pouls
- Parkinson's disease claims 90,000 new American lives each year into its grip, and no existing treatment can slow the neurological unraveling it causes — only soften its symptoms.
- The mystery of how a toxic protein jumps from a dying brain cell into a healthy neighbor has persisted for years, leaving researchers without a clear point of intervention.
- Yale's team engineered 4,400 distinct cell types to find what α-synuclein clings to on the neuron surface, and two proteins — mGluR4 and NPDC1 — emerged as the critical gatekeepers in dopamine-producing regions of the brain.
- Mice genetically stripped of these proteins showed no toxic accumulation and no Parkinson's-like symptoms when exposed to the misfolded protein, while normal mice deteriorated as expected.
- With an aging American population set to expand the ranks of those at risk, the pressure to convert this mouse-model breakthrough into human therapies is both scientific and demographic.
For decades, Parkinson's disease has been understood as a story of accumulation — a toxic protein spreading through the brain like a slow fire — yet the door through which that fire passed remained unknown. Researchers at Yale have now identified two proteins, mGluR4 and NPDC1, that serve as that doorway, ferrying misfolded α-synuclein from dying neurons into healthy ones. When those proteins were removed in mice, the disease stopped advancing entirely. In a condition that has long offered patients only the management of symptoms rather than the slowing of fate, this discovery marks a meaningful turn in the road.
In the basement labs of Yale's neuroscience department, researchers have spent years watching α-synuclein — the toxic protein at the heart of Parkinson's disease — spread from one brain cell to the next. They knew it was happening. What they didn't know was how. A new study published in Nature Communications has finally identified the mechanism: two proteins embedded in the neuron's surface membrane, mGluR4 and NPDC1, that act as transporters for the misfolded protein. When researchers blocked these proteins in mice, the disease stopped advancing.
Parkinson's is a progressive neurological disorder affecting 1.1 million Americans, with nearly 90,000 new diagnoses each year. It erodes motor function gradually — tremors, balance loss, slowed movement — and has no cure. Current treatments address symptoms but leave the underlying degeneration untouched. That gap is precisely what makes this Yale discovery significant.
Stephen Strittmatter, chair of Yale's Department of Neuroscience, led the work. His team began with a deceptively simple question: what does α-synuclein attach to when it arrives at a healthy neuron's surface? To find out, they engineered 4,400 different cell groups, each displaying a unique surface protein, then exposed them all to the misfolded protein. Of the 16 that showed any interaction, two stood out — mGluR4 and NPDC1, both found on the dopamine-producing neurons of the substantia nigra, the brain region most devastated by Parkinson's.
When mice were engineered to lack these proteins and then exposed to α-synuclein, they showed neither toxic accumulation nor Parkinson's-like symptoms. Normal mice, by contrast, deteriorated. In a separate Parkinson's mouse model, removing either gene reduced symptom progression and lowered mortality risk. The two proteins, it emerged, work in tandem to carry the disease forward.
The path from mouse model to human therapy is long, but Strittmatter's team has at least made it visible. As the American population ages and the number of people at risk for neurodegenerative disease grows, the urgency of that translation will only deepen.
In the basement labs of Yale's neuroscience department, researchers have been watching a toxic protein do its work—spreading from one brain cell to the next, leaving damage in its wake. That protein is called α-synuclein, and it is the hallmark of Parkinson's disease. For years, scientists knew it was there, knew it was spreading, but didn't fully understand how it crossed from a dying neuron into a healthy one. A new study published in Nature Communications has identified the gatekeepers: two proteins embedded in the cell membrane called mGluR4 and NPDC1. When researchers blocked these proteins in mice, the disease simply stopped advancing.
Parkinson's is a progressive neurological disorder that destroys brain cells gradually over time. The disease manifests in the body as tremors, balance problems, and slowed movement—symptoms that worsen as the toxic protein accumulates in the motor neurons. About 1.1 million Americans are living with Parkinson's right now, and nearly 90,000 new cases are diagnosed each year. The disease has no cure. Current treatments manage symptoms but do not slow the underlying degeneration. This is why the Yale discovery matters: it points to a mechanism that could, in theory, be interrupted.
Stephen Strittmatter, chair of the Department of Neuroscience at Yale School of Medicine, led the research. His team started with a straightforward question: if α-synuclein needs to get inside healthy neurons, what is it attaching to on the cell surface? To answer it, they engineered 4,400 different groups of cells, each one displaying a different surface protein. Then they exposed all of them to misfolded α-synuclein and watched what stuck. Most proteins showed no interaction at all. But 16 of them did bind to the toxic protein. Two stood out: mGluR4 and NPDC1, both found on dopamine-producing neurons in the substantia nigra—the exact brain region most ravaged by Parkinson's disease.
The next step was to test whether these proteins were actually responsible for transporting the misfolded protein into cells. Strittmatter's team created mice that lacked functional mGluR4 or NPDC1, then exposed them to α-synuclein. The results were striking. Normal mice developed accumulations of the toxic protein in their brains and went on to show Parkinson's-like symptoms. The engineered mice did not. In a separate mouse model of Parkinson's disease, removing either of these genes reduced symptom progression and lowered the risk of death. The proteins, it turned out, work as partners in the transport process.
What makes this finding significant is not just that it explains a mechanism, but that it suggests a target for intervention. Existing Parkinson's treatments are palliative—they help people feel better, but they do not slow the disease itself. If you could block mGluR4 and NPDC1, you might be able to prevent α-synuclein from spreading between neurons in the first place. You might be able to slow the progression, or even halt it. Strittmatter notes that the need for such therapies will only grow more urgent. The American population is aging. The number of people over 65 is projected to rise substantially in the coming decades, which means the population at risk for Parkinson's and other neurodegenerative diseases will expand accordingly. The work ahead is to translate what works in mice into treatments that work in people—a path that is long, but now at least a little clearer.
Citations marquantes
If we understood how it gets into neurons, we could perhaps block or slow down the progression of the disease. But to do that, we need to understand the molecular mechanism of how it spreads.— Stephen Strittmatter, Yale Department of Neuroscience
We have an aging population. How we can stop or slow neurons from dying is an enormous problem. This is really the time to make some inroads into figuring out how to slow it down.— Stephen Strittmatter
Envie de l'histoire complète ?
Lire l'original sur ScienceDaily ↗
Health & Medicine